MedImmune Advances Three Oncology Programs Into the Clinic

GAITHERSBURG, Md., Aug. 10 /PRNewswire/ -- MedImmune today announced that it has advanced three oncology antibody programs into Phase 1 clinical development within the past six months. All three of the antibody candidates will target a variety of advanced solid tumors, but via different pathways.

"Cancer research has long been a priority focus area at MedImmune and we are proud of the organization's hard work to achieve first-time-in-human-status for all three candidates," said Laurence Moore, M.D., Ph.D., vice president, clinical development, oncology. "We look forward to continuing to evaluate how managing the various biological targets inherent in these very different antibodies may potentially lead to better health outcomes for patients suffering from a myriad of cancers."

About MedImmune

MedImmune, the worldwide biologics business for AstraZeneca PLC , has approximately 3,100 employees worldwide and is headquartered in Gaithersburg, Maryland. With an advancing pipeline of promising candidates, we aim to be the next revolutionary force in biotechnology by delivering life-changing products, industry-leading performance, and a tireless commitment to improving patient health. For more information, visit MedImmune's website at www.medimmune.com.

SOURCE MedImmune

CONTACT: Media, Sidoney Atse of MedImmune, +1-301-398-5990

Web site: http://www.medimmune.com/